Total Payments
$21,390
2024 Payments
$3,528
Companies
76
Transactions
1,233
Medicare Patients
26,654
Medicare Billing
$8.7M
Payment Breakdown by Category
Food & Beverage$20,346 (95.1%)
Education$1,043 (4.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $20,346 | 1,209 | 95.1% |
| Education | $1,043 | 24 | 4.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,943 | 133 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,533 | 77 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,424 | 82 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,234 | 72 | $0 (2024) |
| Genentech USA, Inc. | $1,162 | 93 | $0 (2024) |
| Janssen Biotech, Inc. | $1,043 | 42 | $0 (2024) |
| PFIZER INC. | $992.27 | 73 | $0 (2024) |
| Incyte Corporation | $901.35 | 44 | $0 (2024) |
| Amgen Inc. | $792.09 | 46 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $574.37 | 31 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,528 | 170 | Novartis Pharmaceuticals Corporation ($307.91) |
| 2023 | $3,513 | 174 | Janssen Biotech, Inc. ($306.10) |
| 2022 | $3,068 | 161 | Janssen Biotech, Inc. ($276.56) |
| 2021 | $2,923 | 166 | AstraZeneca Pharmaceuticals LP ($256.11) |
| 2020 | $2,114 | 131 | E.R. Squibb & Sons, L.L.C. ($281.09) |
| 2019 | $2,303 | 153 | E.R. Squibb & Sons, L.L.C. ($294.60) |
| 2018 | $1,897 | 129 | E.R. Squibb & Sons, L.L.C. ($363.25) |
| 2017 | $2,045 | 149 | Genentech USA, Inc. ($351.34) |
All Payment Transactions
1,233 individual payment records from CMS Open Payments — Page 1 of 50
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $29.50 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $19.91 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: Oncology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $32.96 | General |
| Category: Oncology | ||||||
| 12/03/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $17.77 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $27.31 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $28.87 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $18.51 | General |
| Category: Oncology | ||||||
| 11/21/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $23.41 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Janssen Biotech, Inc. | TALVEY (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: Oncology | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.83 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $25.11 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $19.48 | General |
| Category: Hematology/Oncology | ||||||
| 11/01/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: Oncology | ||||||
| 10/31/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $27.90 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $18.12 | General |
| Category: Oncology | ||||||
| 10/26/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.23 | General |
| 10/25/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $14.85 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Genentech USA, Inc. | Itovebi (Biological), Perjeta, Phesgo | Food and Beverage | In-kind items and services | $15.82 | General |
| Category: BioOncology | ||||||
| 10/22/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $21.75 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 53 | 6,617 | 228,834 | $8.6M | $2.7M |
| 2022 | 48 | 6,153 | 187,889 | $5.6M | $1.7M |
| 2021 | 55 | 6,529 | 227,152 | $7.1M | $2.2M |
| 2020 | 58 | 7,355 | 249,417 | $7.4M | $2.2M |
Total Patients
26,654
Total Services
893,292
Medicare Billing
$8.7M
Procedure Codes
214
All Medicare Procedures & Services
214 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 17 | 27,800 | $3.6M | $1.2M | 32.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 150 | 21,420 | $856,800 | $395,463 | 46.2% |
| J1556 | Injection, immune globulin (bivigam), 500 mg | Office | 2023 | 12 | 3,000 | $525,000 | $168,719 | 32.1% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 61 | 8,300 | $597,600 | $136,341 | 22.8% |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | Office | 2023 | 14 | 4,356 | $257,004 | $110,739 | 43.1% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 12 | 2,690 | $336,250 | $95,699 | 28.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 615 | 1,135 | $170,250 | $72,536 | 42.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 98 | 772 | $177,560 | $72,258 | 40.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 386 | 666 | $116,550 | $60,253 | 51.7% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 38 | 54,000 | $164,700 | $47,611 | 28.9% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 27 | 5,600 | $168,000 | $34,187 | 20.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 770 | 3,822 | $57,330 | $28,982 | 50.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 693 | 2,784 | $194,880 | $28,742 | 14.7% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 55 | 60,180 | $180,540 | $24,907 | 13.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 202 | 481 | $72,150 | $21,312 | 29.5% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 435 | 1,212 | $60,600 | $19,262 | 31.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 151 | 151 | $56,625 | $17,588 | 31.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 77 | 726 | $108,900 | $15,352 | 14.1% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 21 | 105 | $63,000 | $14,169 | 22.5% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 261 | 598 | $44,850 | $11,037 | 24.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 141 | 935 | $93,500 | $10,454 | 11.2% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 283 | 700 | $70,000 | $9,339 | 13.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 243 | 871 | $30,485 | $8,953 | 29.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 45 | 189 | $28,350 | $8,821 | 31.1% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 181 | 371 | $18,550 | $7,483 | 40.3% |
About Dr. Dirk Davidson, MD
Dr. Dirk Davidson, MD is a Specialist healthcare provider based in Crossville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/06/2005. The National Provider Identifier (NPI) number assigned to this provider is 1659369429.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dirk Davidson, MD has received a total of $21,390 in payments from pharmaceutical and medical device companies, with $3,528 received in 2024. These payments were reported across 1,233 transactions from 76 companies. The most common payment nature is "Food and Beverage" ($20,346).
As a Medicare-enrolled provider, Davidson has provided services to 26,654 Medicare beneficiaries, totaling 893,292 services with total Medicare billing of $8.7M. Data is available for 4 years (2020–2023), covering 214 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Crossville, TN
- Active Since 10/06/2005
- Last Updated 12/28/2022
- Taxonomy Code 174400000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1659369429
Products in Payments
- OPDIVO (Biological) $1,354
- KEYTRUDA (Biological) $1,094
- IMBRUVICA (Drug) $578.46
- JAKAFI (Drug) $542.69
- KISQALI (Drug) $459.47
- Lenvima (Drug) $382.18
- XTANDI (Drug) $362.37
- IBRANCE (Drug) $342.23
- LIBTAYO (Biological) $342.05
- DARZALEX (Biological) $331.30
- MEKINIST (Drug) $308.00
- ADCETRIS (Biological) $297.94
- CALQUENCE (Drug) $297.63
- NINLARO (Drug) $297.07
- Enhertu (Drug) $295.72
- TAGRISSO (Drug) $290.82
- REBLOZYL (Biological) $284.92
- Nubeqa (Drug) $246.09
- KRAZATI (Drug) $218.15
- PADCEV (Biological) $212.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.